(Q38017870)

27 August 2017

title

Metabolome and inflammasome in inflammatory bowel disease (English)

1 reference

inflammatory bowel diseases

27 August 2017

main subject

0 references

1 reference

Radu M Nanau

1

1 reference

27 August 2017

Manuela G Neuman

series ordinal

2

1 reference

27 August 2017

publication date

14 September 2011

1 reference

27 August 2017

published in

Translational Research

1 reference

27 August 2017

volume

160

1 reference

27 August 2017

issue

1

1 reference

27 August 2017

page(s)

1-28

1 reference

Immune dysfunction in inflammatory bowel disease

27 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2011.08.006

Uncoupling gene-diet interactions in inflammatory bowel disease (IBD)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2011.08.006

Inflammatory bowel disease, gut bacteria and probiotic therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2011.08.006

Environmental risk factors in Crohn's disease and ulcerative colitis: an update

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2011.08.006

New insights into IBD epidemiology: Are there any lessons for treatment?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2011.08.006

The prevalence and geographic distribution of Crohn's disease and ulcerative colitis in the United States

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2011.08.006

Epidemiology of Inflammatory Bowel Disease among Children in Poland

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2011.08.006

Iliac bone histomorphometry in children with newly diagnosed inflammatory bowel disease.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2011.08.006

Characteristics of inflammatory bowel disease with onset during the first year of life

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2011.08.006

Environmental factors in the development of chronic inflammation: a case-control study on risk factors for Crohn's disease within New Zealand.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2011.08.006

CEACAM1 and the regulation of mucosal inflammation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2011.08.006

Targeted therapies in inflammatory bowel disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2011.08.006

Antibodies against laminaribioside and chitobioside are novel serologic markers in Crohn's disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2011.08.006

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2011.08.006

Diagnostic value of serological assays in pediatric inflammatory bowel disorders

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2011.08.006

Seroreactivity to microbial components in Crohn's disease is associated with ileal involvement, noninflammatory disease behavior and NOD2/CARD15 genotype, but not with risk for surgery in a Hungarian cohort of IBD patients.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2011.08.006

Anti-Saccharomyces cerevisiae antibodies status is associated with oral involvement and disease severity in Crohn disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2011.08.006

Predictive value of serologic markers in a population-based Norwegian cohort with inflammatory bowel disease.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2011.08.006

Anticarbohydrate antibodies as markers of inflammatory bowel disease in a Central European cohort

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2011.08.006

Association of the novel serologic anti-glycan antibodies anti-laminarin and anti-chitin with complicated Crohn's disease behavior

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2011.08.006

Novel Anti-Glycan Antibodies Related to Inflammatory Bowel Disease Diagnosis and Phenotype

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2011.08.006

Autoantibodies pANCA, GAB and PAB in inflammatory bowel disease: prevalence, characteristics and diagnostic value

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2011.08.006

Analysis of serum antibodies in patients suspected of having inflammatory bowel disease.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2011.08.006

Fecal calprotectin: a quantitative marker of colonic inflammation in children with inflammatory bowel disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2011.08.006

Faecal S100A12 as a non-invasive marker distinguishing inflammatory bowel disease from irritable bowel syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2011.08.006

Fecal S100A12 and fecal calprotectin as noninvasive markers for inflammatory bowel disease in children

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2011.08.006

Fecal calprotectin is useful in predicting disease relapse in pediatric inflammatory bowel disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2011.08.006

Clinical role of calprotectin assay in determining histological relapses in children affected by inflammatory bowel diseases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2011.08.006

Fecal S100A12: a novel noninvasive marker in children with Crohn's disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2011.08.006

Serum and mucosal S100 proteins, calprotectin (S100A8/S100A9) and S100A12, are elevated at diagnosis in children with inflammatory bowel disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2011.08.006

Moderate performance of serum S100A12, in distinguishing inflammatory bowel disease from irritable bowel syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2011.08.006

Phagocyte-specific S100 proteins are released from affected mucosa and promote immune responses during inflammatory bowel disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2011.08.006

Utility of fecal lactoferrin in identifying Crohn disease activity in children

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2011.08.006

Relationship between fecal lactoferrin and inflammatory bowel disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2011.08.006

Faecal lactoferrin--a novel test to differentiate between the irritable and inflamed bowel?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2011.08.006

Accuracy of four fecal assays in the diagnosis of colitis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2011.08.006

Serum soluble TNF receptor I and II levels correlate with disease activity in IBD patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2011.08.006

Mucosal T-cell immunoregulation varies in early and late inflammatory bowel disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2011.08.006

Detection of galectin-3 in patients with inflammatory bowel diseases: new serum marker of active forms of IBD?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2011.08.006

Expression of the high-affinity IgG receptor FcRI (CD64) in patients with inflammatory bowel disease: a new biomarker for gastroenterologic diagnostics

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2011.08.006

CXCL16 is a surrogate marker of inflammatory bowel disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2011.08.006

Comparison of RANTES expression in Crohn's disease and ulcerative colitis: an aid in the differential diagnosis?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2011.08.006

Increased circulating concentrations of growth-related oncogene (GRO)-alpha in patients with inflammatory bowel disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2011.08.006

Circulating adipokines and the protective effects of hyperinsulinemia in inflammatory bowel disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2011.08.006

Urine-based detection of intestinal tight junction loss

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2011.08.006

Granulocyte-macrophage colony-stimulating factor autoantibodies in murine ileitis and progressive ileal Crohn's disease.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2011.08.006

High levels of proinflammatory cytokines, but not markers of tissue injury, in unaffected intestinal areas from patients with IBD

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2011.08.006

Reduced immunostaining for c-kit receptors in mucosal mast cells in inflammatory bowel disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2011.08.006

Differential protein expression profile in the intestinal epithelium from patients with inflammatory bowel disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2011.08.006

New insights into the pathogenesis of inflammatory bowel disease: transcription factors analysis in bioptic tissues from pediatric patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2011.08.006

Tumor necrosis factor-α represses the expression of NHE2 through NF-κB activation in intestinal epithelial cell model, C2BBe1

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2011.08.006

Metabolic assessment of gradual development of moderate experimental colitis in IL-10 deficient mice.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2011.08.006

Loss of Toll-like receptor 2 and 4 leads to differential induction of endoplasmic reticulum stress and proapoptotic responses in the intestinal epithelium under conditions of chronic inflammation.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2011.08.006

Urinary metabolic profiles of inflammatory bowel disease in interleukin-10 gene-deficient mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2011.08.006

Interleukin-10 blocked endoplasmic reticulum stress in intestinal epithelial cells: impact on chronic inflammation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2011.08.006

Intestinal epithelial serum amyloid A modulates bacterial growth in vitro and pro-inflammatory responses in mouse experimental colitis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2011.08.006

Proinflammatory role of vasopressin through V1b receptors in hapten-induced experimental colitis in rodents: implication in IBD.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2011.08.006

Adhesion molecule therapeutics in IBD

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2011.08.006

Mucosal gene expression of cell adhesion molecules, chemokines, and chemokine receptors in patients with inflammatory bowel disease before and after infliximab treatment.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2011.08.006

Vascular cell adhesion molecule-1 expression in human intestinal microvascular endothelial cells is regulated by PI 3-kinase/Akt/MAPK/NF-kappaB: inhibitory role of curcumin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2011.08.006

Blockage of angiotensin II type 1 receptor regulates TNF-alpha-induced MAdCAM-1 expression via inhibition of NF-kappaB translocation to the nucleus and ameliorates colitis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2011.08.006

Anti-adhesion molecule therapies in inflammatory bowel disease: touch and go.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2011.08.006

Epithelial tight junctions in intestinal inflammation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2011.08.006

10.1016/J.TRSL.2011.08.006

7 January 2021

Identifiers

DOI

1 reference

27 August 2017

1 reference